These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 18483323)

  • 1. Urinary metalloproteinases: noninvasive biomarkers for breast cancer risk assessment.
    Pories SE; Zurakowski D; Roy R; Lamb CC; Raza S; Exarhopoulos A; Scheib RG; Schumer S; Lenahan C; Borges V; Louis GW; Anand A; Isakovich N; Hirshfield-Bartek J; Wewer U; Lotz MM; Moses MA
    Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1034-42. PubMed ID: 18483323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary ADAM12 and MMP-9/NGAL complex detect the presence of gastric cancer.
    Shimura T; Dagher A; Sachdev M; Ebi M; Yamada T; Yamada T; Joh T; Moses MA
    Cancer Prev Res (Phila); 2015 Mar; 8(3):240-8. PubMed ID: 25591790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary concentrations of ADAM 12 from breast cancer patients pre- and post-surgery vs. cancer-free controls: a clinical study for biomarker validation.
    Nyren-Erickson EK; Bouton M; Raval M; Totzauer J; Mallik S; Alberto N
    J Negat Results Biomed; 2014 Apr; 13():5. PubMed ID: 24690292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage.
    Roy R; Wewer UM; Zurakowski D; Pories SE; Moses MA
    J Biol Chem; 2004 Dec; 279(49):51323-30. PubMed ID: 15381692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species.
    Roy R; Louis G; Loughlin KR; Wiederschain D; Kilroy SM; Lamb CC; Zurakowski D; Moses MA
    Clin Cancer Res; 2008 Oct; 14(20):6610-7. PubMed ID: 18927302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical outcome of biopsy-proven lobular neoplasia: is there any difference between lobular carcinoma in situ and atypical lobular hyperplasia?
    Ibrahim N; Bessissow A; Lalonde L; Mesurolle B; Trop I; Lisbona A; El-Khoury M
    AJR Am J Roentgenol; 2012 Feb; 198(2):288-91. PubMed ID: 22268170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast Cancer Risk and Follow-up Recommendations for Young Women Diagnosed with Atypical Hyperplasia and Lobular Carcinoma In Situ (LCIS).
    McEvoy MP; Coopey SB; Mazzola E; Buckley J; Belli A; Polubriaginof F; Merrill AL; Tang R; Garber JE; Smith BL; Gadd MA; Specht MC; Guidi AJ; Roche CA; Hughes KS
    Ann Surg Oncol; 2015 Oct; 22(10):3346-9. PubMed ID: 26242364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening breast magnetic resonance imaging in women with atypia or lobular carcinoma in situ.
    Schwartz T; Cyr A; Margenthaler J
    J Surg Res; 2015 Feb; 193(2):519-22. PubMed ID: 25277350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ADAM12 redistributes and activates MMP-14, resulting in gelatin degradation, reduced apoptosis and increased tumor growth.
    Albrechtsen R; Kveiborg M; Stautz D; Vikeså J; Noer JB; Kotzsh A; Nielsen FC; Wewer UM; Fröhlich C
    J Cell Sci; 2013 Oct; 126(Pt 20):4707-20. PubMed ID: 24006261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary biomarkers predict brain tumor presence and response to therapy.
    Smith ER; Zurakowski D; Saad A; Scott RM; Moses MA
    Clin Cancer Res; 2008 Apr; 14(8):2378-86. PubMed ID: 18413828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma.
    Gerhards S; Jung K; Koenig F; Daniltchenko D; Hauptmann S; Schnorr D; Loening SA
    Urology; 2001 Apr; 57(4):675-9. PubMed ID: 11306379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated urinary ADAM12 protein levels in lithium-treated bipolar patients.
    Nadri C; Bersudsky Y; Belmaker RH; Agam G
    J Neural Transm (Vienna); 2007; 114(4):473-7. PubMed ID: 17066252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular profiling of ADAM12 in human bladder cancer.
    Fröhlich C; Albrechtsen R; Dyrskjøt L; Rudkjaer L; Ørntoft TF; Wewer UM
    Clin Cancer Res; 2006 Dec; 12(24):7359-68. PubMed ID: 17189408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lobular carcinoma in situ or atypical lobular hyperplasia at core-needle biopsy: is excisional biopsy necessary?
    Foster MC; Helvie MA; Gregory NE; Rebner M; Nees AV; Paramagul C
    Radiology; 2004 Jun; 231(3):813-9. PubMed ID: 15105449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical lobular hyperplasia or lobular carcinoma in situ at core-needle breast biopsy.
    Berg WA; Mrose HE; Ioffe OB
    Radiology; 2001 Feb; 218(2):503-9. PubMed ID: 11161169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy.
    Adepoju LJ; Symmans WF; Babiera GV; Singletary SE; Arun B; Sneige N; Pusztai L; Buchholz TA; Sahin A; Hunt KK; Meric-Bernstam F; Ross MI; Ames FC; Kuerer HM
    Cancer; 2006 Jan; 106(1):42-50. PubMed ID: 16333852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of MRI screening for breast cancer in high-risk patients with LCIS and atypical hyperplasia.
    Port ER; Park A; Borgen PI; Morris E; Montgomery LL
    Ann Surg Oncol; 2007 Mar; 14(3):1051-7. PubMed ID: 17206485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer risk factors in younger and older women.
    Chun J; Pocock B; Joseph KA; El-Tamer M; Klein L; Schnabel F
    Ann Surg Oncol; 2009 Jan; 16(1):96-9. PubMed ID: 18979140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients.
    Ranuncolo SM; Armanasco E; Cresta C; Bal De Kier Joffe E; Puricelli L
    Int J Cancer; 2003 Sep; 106(5):745-51. PubMed ID: 12866035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the accuracy of the Gail model in women with atypical hyperplasia.
    Pankratz VS; Hartmann LC; Degnim AC; Vierkant RA; Ghosh K; Vachon CM; Frost MH; Maloney SD; Reynolds C; Boughey JC
    J Clin Oncol; 2008 Nov; 26(33):5374-9. PubMed ID: 18854574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.